Olema Oncology, Inc. (OLMA) stock
OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.56+0.04 (+0.53%)
Close on Nov 13, 2026Market cap $661.48MP/E –Yield –
Olema Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Olema Oncology's ebitda for the twelve months ending Sep 30, 2026 was -$252.27M. For fiscal 2025 it was -$178.21M. The highest annual figure on record is -$4.31M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$178.21M | – |
| FY2024 | Dec 31, 2024 | -$141.87M | – |
| FY2023 | Dec 31, 2023 | -$104.58M | – |
| FY2022 | Dec 31, 2022 | -$106.63M | – |
| FY2021 | Dec 31, 2021 | -$71.33M | – |
| FY2020 | Dec 31, 2020 | -$21.52M | – |
| FY2019 | Dec 31, 2019 | -$4.31M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$77.43M | – |
| Q2 FY2026 | Jun 30, 2026 | -$67.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$49.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$45.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$30.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.17M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.44M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.13M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.48M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.04M | – |
See a number that looks wrong?